Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2022

View Archived Issues

Tyrosine kinase inhibitor NTRC-0652-0 shows promise for the treatment of cholangiocarcinoma

New prolyl endopeptidase inhibitors identified at Accure Therapeutics

ReViral describes new compounds for respiratory syncytial virus infections

Mcl-1 inhibitors discovered at Janssen

3M Innovative Properties divulges new Toll-like receptor 7 agonists

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent Bcl-2 and/or Bcl-X inhibitors

Endothelial BCAR1 expression associated with antiangiogenic therapy resistance

Discovery of novel MBL inhibitors as promising beta-lactam antibiotics

Epigenetic-mediated immune mechanisms identified in TB

A microbiota-macrophage-iron axis regulates hematopoietic stem cell fate decisions under stress

A comprehensive catalog of functional cell types and cellular states in human brain metastases

Targeting PPARalpha-ACOT12 axis as a potential new therapeutic strategy for osteoarthritis

PLA2-IIA modulates immunity through its interaction with microbiota

CIRM grant supports Juvena's preclinical work on JUV-161 for myotonic dystrophy type 1

Brickell licenses rights to Carna's STING antagonists for autoimmune and inflammatory diseases

Anakuria's AT-20494 to be studied for ADPKD and other indications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...